Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-4.91% $0.370
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 8.74 mill |
EPS: | -0.720 |
P/E: | -0.510 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 23.63 mill |
Avg Daily Volume: | 0.856 mill |
RATING 2024-04-25 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | n/a | n/a | ||||
Asset | n/a | n/a | n/a | n/a | ||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.510 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.09x |
Company: PE -0.510 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.121 (-67.21%) $-0.249 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 0.332 - 0.408 ( +/- 10.27%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2013-11-04 | Austin Josiah T | Sell | 25 400 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-11-05 | Austin Josiah T | Sell | 23 922 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-10-25 | Austin Josiah T | Sell | 62 591 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-10-28 | Austin Josiah T | Sell | 37 409 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-10-29 | Austin Josiah T | Sell | 1 100 | Sponsored ADRs, each convertible into 25 ordinary shares |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 5 568 614 | Sell: 243 947 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.370 (-4.91% ) |
Volume | 0.165 mill |
Avg. Vol. | 0.856 mill |
% of Avg. Vol | 19.33 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.